Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Dopolnjena priporočila za sistemsko zdravljenje bolnikov z napredovalim rakom debelega črevesa in danke - 2009
Authors:ID Reberšek, Martina (Author)
ID Ocvirk, Janja (Author)
ID Hlebanja, Zvezdana (Author)
ID Benedik, Jernej (Author)
ID Volk, Neva (Author)
Files:.pdf PDF - Presentation file, download (64,83 KB)
MD5: 66BA2CF721D7A4FE8F57CD0091B7B3E6
PID: 20.500.12556/dirros/b30a5d15-9e99-4e50-b019-d34131b4260a
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Metastatski rak debelega črevesa in danke je večinoma še vedno neozdravljiva bolezen, vendar sta se prognoza in preživetje teh bolnikov v zadnjih 6 letih močno izboljšala. Od srednjega 10-mesečnega preživetja, ki smo ga dosegali z zdravljenjem s 5-fluorouracilom, ki je bilo pred nekaj leti edino učinkovito zdravilo za zdravljenje teh bolnikov, smo prešli na preživetje, daljše od 20 mesecev, kar so omogočili novi citostatiki. Kombinirano zdravljenje omogoča boljšo kakovost življenja in daljše remisije, s tem pa tudi daljše celostne preživetje. Uporaba kombinacije citostatikov s tarčnimi zdravili vodi v nadaljnje podaljšanje srednjega preživetja teh bolnikov, srednje preživetje je tako daljše od 30 mesecev. To zdravljenje v kombinaciji z operacijo pljučnih ali jetrnih zasevkov pa omogoča tudi zazdravitve. Pomembna letošnja novost je določanje mutacij na genu KRAS. Za raka debelega črevesja in danke je gen KRAS prvi biomarker, ki napoveduje, kako se bodo bolniki odzvali na neko zdravljenje.
Publication status:Published
Publication version:Version of Record
Year of publishing:2009
Number of pages:str. 11-15
Numbering:Letn. 13, št. 1
PID:20.500.12556/DiRROS-8935 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-J1355XRY
COBISS.SI-ID:25689049 New window
Copyright:by Authors
Note:BSDOCID145198;
Publication date in DiRROS:31.08.2018
Views:3621
Downloads:881
Metadata:XML DC-XML DC-RDF
:
REBERŠEK, Martina, OCVIRK, Janja, HLEBANJA, Zvezdana, BENEDIK, Jernej and VOLK, Neva, 2009, Dopolnjena priporočila za sistemsko zdravljenje bolnikov z napredovalim rakom debelega črevesa in danke - 2009. Onkologija [online]. 2009. Vol. 13, no. 1, p. 11–15. [Accessed 19 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=8935
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Updated Guidelines for Systemic Treatment of Patients with Advanced Colorectal Cancer - 2009
Abstract:In most cases, metastatic colorectal cancer is incurable; however, the prognosis and survival of these patients have significantly improved in the last six years. A few years back, the only efficient drug for colorectal carcinoma, 5-fluoruracil, yielded the mean survival of 10 months, whereas today, the survival rates of 20 months or more may be obtained by using new citostatics. In the last six years, six new drugs were registered for the treatment of metastatic colorectal cancer. These are three citostatics (capecitabine, irinotecan, oxaliplatin) and three target drugs (cetuximab, bevacizumab, panitumumab). A combined treatment assures a better quality of life, and longer remissions and overall survival. The combination of cytostatics and target drugs improves particularly the mean survival rate which may be longer than 30 months. These combinations of drugs used together with surgical treatment of lung and liver metastases may result in complete remission. An important research achievement of this year is the determination of KRAS mutations. The KRAS gene is the first biomarker that predicts how well patients will respond to certain combination of treatment.


Archive

niGradiv

Back